Sirolimus‐based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

Norman M. Kneteman, José Oberholzer, Mohammed Al Saghier, Glenda A. Meeberg, Maurice Blitz, Mang M. Ma, Winnie W.S. Wong, Klaus Gutfreund, Andrew L. Mason, Larry D. Jewell, A.M. James Shapiro, Vincent G. Bain, David L. Bigam – 16 September 2004 – An increasing number of patients with hepatocellular carcinoma (HCC) are undergoing evaluation for listing for liver transplantation. Criteria for selection require ongoing review for suitability.

Impact of tacrolimus versus cyclosporine in hepatitis C virus‐infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial

Paul Martin, Ronald W. Busuttil, Robert M. Goldstein, Jeffrey S. Crippin, Goran B. Klintmalm, William E. Fitzsimmons, Carol Uleman – 16 September 2004 – Hepatitis C virus (HCV)‐induced cirrhosis is the commonest indication for orthotopic liver transplantation, but HCV recurrence is nearly universal and may worsen patient / graft outcomes. The frequency and severity of HCV recurrence has apparently increased in recent years, raising concern about a possible role for newer immunosuppression regimens in this increase, including potentially tacrolimus.

Survival among pediatric liver transplant recipients: Impact of segmental grafts

Peter L. Abt, Rachel Rapaport‐Kelz, Niraj M. Desai, Adam Frank, Seema Sonnad, Elizabeth Rand, James F. Markmann, Abraham Shaked, Kim M. Olthoff – 16 September 2004 – Segmental liver transplantation with living donor (LD), reduced cadaveric (Reduced), and split cadaveric (Split) allografts has expanded the availability of size‐appropriate organs for pediatric recipients. The relevance of recipient age to the selection of graft type has not been fully explored, but could offer the potential to maximize recipient outcome and donor utilization.

Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation

Arie Regev, Enrique Molina, Rosana Moura, Pablo A. Bejarano, Amr Khaled, Phillip Ruiz, Kris Arheart, Mariana Berho, Cinthia B. Drachenberg, Patricia Mendez, Christopher O'Brien, Lennox Jeffers, Andreas Tzakis, Eugene R. Schiff – 16 September 2004 – Histopathologic assessment is considered essential for the differentiation of recurrent hepatitis C (RHC) from acute cellular rejection (ACR) after liver transplantation (LT); however, there is limited information regarding its reliability.

Increased prothrombin time and platelet counts in living donor right hepatectomy: Implications for epidural anesthesia

Antonio Siniscalchi, Bruno Begliomini, Lesley De Pietri, Vanessa Braglia, Matteo Gazzi, Michele Masetti, Fabrizio Di Benedetto, Antonio D. Pinna, Charles M. Miller, Alberto Pasetto – 30 August 2004 – The risks and benefits of adult‐to‐adult living donor liver transplantation need to be carefully evaluated. Anesthetic management includes postoperative epidural pain relief; however, even patients with a normal preoperative coagulation profile may suffer transient postoperative coagulation derangement.

Orthotopic liver transplantation for portosystemic encephalopathy in an adult with congenital absence of the portal vein

Maciej Wojcicki, Elizabeth B. Haagsma, Annette S.H. Gouw, Maarten J.H. Slooff, Robert J. Porte – 30 August 2004 – Congenital absence of the portal vein (CAPV) is a very rare venous malformation in which mesenteric venous blood drains directly into the systemic circulation. There is no portal perfusion of the liver and no portal hypertension. This abnormality is usually coincidentally discovered in children, the majority of whom have no signs of encephalopathy and only slightly abnormal liver function tests.

Subscribe to